13-32316463-G-T
Variant summary
Our verdict is Pathogenic. The variant received 20 ACMG points: 20P and 0B. PVS1PS1_ModeratePM2PP5_Very_Strong
The NM_000059.4(BRCA2):c.3G>T(p.Met1?) variant causes a start lost change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000059.4 start_lost
Scores
Clinical Significance
Conservation
Publications
- breast-ovarian cancer, familial, susceptibility to, 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), ClinGen
- Fanconi anemia complementation group D1Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, ClinGen, G2P
- pancreatic cancer, susceptibility to, 2Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- sarcomaInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- hereditary breast ovarian cancer syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- medulloblastomaInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 20 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000059.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| BRCA2 | NM_000059.4 | MANE Select | c.3G>T | p.Met1? | start_lost | Exon 2 of 27 | NP_000050.3 | ||
| BRCA2 | NM_001432077.1 | c.3G>T | p.Met1? | start_lost | Exon 2 of 27 | NP_001419006.1 | |||
| BRCA2 | NM_001406720.1 | c.3G>T | p.Met1? | start_lost | Exon 2 of 27 | NP_001393649.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| BRCA2 | ENST00000380152.8 | TSL:5 MANE Select | c.3G>T | p.Met1? | start_lost | Exon 2 of 27 | ENSP00000369497.3 | ||
| BRCA2 | ENST00000544455.6 | TSL:1 | c.3G>T | p.Met1? | start_lost | Exon 2 of 27 | ENSP00000439902.1 | ||
| BRCA2 | ENST00000614259.2 | TSL:2 | n.3G>T | non_coding_transcript_exon | Exon 1 of 26 | ENSP00000506251.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 2 Pathogenic:2
Hereditary breast ovarian cancer syndrome Pathogenic:2
While this variant is expected to result in an absent protein product, possible rescue of translational initiation by the downstream methionine would lead to the disruption of the N-terminal part of the BRCA2 protein that interacts with PALB2 (residues 18-40), which is critical for BRCA2-mediated homologous recombinational DNA repair (PMID: 16793542, 22678057, 19369211). For these reasons, this variant has been classified as Pathogenic. A different variant (c.3G>A) affecting the same codon observed here (initiator codon) has been reported in individuals affected with breast and/or ovarian cancer (PMID: 21203900, 21769658, 20104584), indicating that this residue may be critical for protein function. This variant has been reported in individuals affected with breast cancer (PMID: 26287763). ClinVar contains an entry for this variant (Variation ID: 37871). This variant is not present in population databases (ExAC no frequency). This sequence change affects the initiator methionine of the BRCA2 mRNA. The next in-frame methionine is located at codon 124, which could potentially rescue translational initiation.
Breast and/or ovarian cancer Pathogenic:1
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.M1? pathogenic mutation (also known as c.3G>T) is located in coding exon 1 of the BRCA2 gene and results from a G to T substitution at nucleotide position 3. This alters the methionine residue at the initiation codon (ATG). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Sequence variations that modify the initiation codon are expected to result in either loss of translation initiation, N-terminal truncation, or cause a shift in the mRNA reading frame. Based on the supporting evidence, this variant is interpreted as a disease-causing mutation.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at